Key features

  • An IgG2a antibody has been developed to specifically target Epstein-Barr Virus (EBV) positive tumours such as Nasopharyngeal (NPC) and Gastric cancer (GC) as well as some lymphomas such as Burkitt, T/NK-Cell and Hodgkin Lymphomas
  • Significant unmet needs for treatment options for advanced and relapsed NPC and GC patients
  • EBV-infected tumour cells are targeted through high specificity for the membrane-bound form of the BARF1 protein over soluble BARF1.

Back to available technologies

Contact us

To enquire about this Available Technology, please contact us.